JP2010531345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531345A5 JP2010531345A5 JP2010514138A JP2010514138A JP2010531345A5 JP 2010531345 A5 JP2010531345 A5 JP 2010531345A5 JP 2010514138 A JP2010514138 A JP 2010514138A JP 2010514138 A JP2010514138 A JP 2010514138A JP 2010531345 A5 JP2010531345 A5 JP 2010531345A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyclopropyl
- amino
- alkoxy
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- -1 methoxy, ethoxy Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FBFWRFSQOQBANB-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2-(2-hydroxyethylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1N(C1=O)C=CN=C1NC1(C=2C(=CC=CC=2)OCCNCCO)CC1 FBFWRFSQOQBANB-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- IRLYGRLEBKCYPY-UHFFFAOYSA-N 2,5-dimethylbenzenesulfonic acid Chemical compound CC1=CC=C(C)C(S(O)(=O)=O)=C1 IRLYGRLEBKCYPY-UHFFFAOYSA-N 0.000 claims 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 1
- ZJWQYMZURGETJD-UHFFFAOYSA-N 3-[3-[[1-[2-(2-aminoethoxy)phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]-n-cyclopropyl-5-fluoro-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1N(C1=O)C=CN=C1NC1(C=2C(=CC=CC=2)OCCN)CC1 ZJWQYMZURGETJD-UHFFFAOYSA-N 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 claims 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920002230 Pectic acid Polymers 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 claims 1
- WABIFCXMZKETLV-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[3-[2-[2-[2-(2-hydroxyethylamino)ethoxy]phenyl]propan-2-ylamino]-2-oxopyrazin-1-yl]-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1N(C1=O)C=CN=C1NC(C)(C)C1=CC=CC=C1OCCNCCO WABIFCXMZKETLV-UHFFFAOYSA-N 0.000 claims 1
- BXNTVZZUMZOUAK-SFHVURJKSA-N n-cyclopropyl-3-fluoro-5-[3-[2-[2-[2-[[(2s)-2-hydroxypropyl]amino]ethoxy]phenyl]propan-2-ylamino]-2-oxopyrazin-1-yl]-4-methylbenzamide Chemical compound C[C@H](O)CNCCOC1=CC=CC=C1C(C)(C)NC(C1=O)=NC=CN1C1=CC(C(=O)NC2CC2)=CC(F)=C1C BXNTVZZUMZOUAK-SFHVURJKSA-N 0.000 claims 1
- HSPRNUYKOMESSJ-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2-[2-hydroxyethyl(methyl)amino]ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]-4-methylbenzamide Chemical compound OCCN(C)CCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 HSPRNUYKOMESSJ-UHFFFAOYSA-N 0.000 claims 1
- SAZVRXTVWZAHBI-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[3-[2-[2-[2-(methylamino)ethoxy]phenyl]propan-2-ylamino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C(C)(C)NC(C1=O)=NC=CN1C1=CC(C(=O)NC2CC2)=CC=C1C SAZVRXTVWZAHBI-UHFFFAOYSA-N 0.000 claims 1
- LFIFOOUCEUUIHK-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=CC=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 LFIFOOUCEUUIHK-UHFFFAOYSA-N 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- 229940014662 pantothenate Drugs 0.000 claims 1
- 235000019161 pantothenic acid Nutrition 0.000 claims 1
- 239000011713 pantothenic acid Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229950010765 pivalate Drugs 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
- 229940114926 stearate Drugs 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 1
- 229950000339 xinafoate Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94641507P | 2007-06-27 | 2007-06-27 | |
| US60/946,415 | 2007-06-27 | ||
| US97816707P | 2007-10-08 | 2007-10-08 | |
| US60/978,167 | 2007-10-08 | ||
| US2944408P | 2008-02-18 | 2008-02-18 | |
| US61/029,444 | 2008-02-18 | ||
| PCT/GB2008/050491 WO2009001132A1 (en) | 2007-06-27 | 2008-06-25 | Pyrazinone derivatives and their use in the treatment of lung diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012211413A Division JP5539473B2 (ja) | 2007-06-27 | 2012-09-25 | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010531345A JP2010531345A (ja) | 2010-09-24 |
| JP2010531345A5 true JP2010531345A5 (enExample) | 2012-07-19 |
| JP5140154B2 JP5140154B2 (ja) | 2013-02-06 |
Family
ID=39745171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514138A Expired - Fee Related JP5140154B2 (ja) | 2007-06-27 | 2008-06-25 | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| JP2012211413A Expired - Fee Related JP5539473B2 (ja) | 2007-06-27 | 2012-09-25 | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012211413A Expired - Fee Related JP5539473B2 (ja) | 2007-06-27 | 2012-09-25 | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8163905B2 (enExample) |
| EP (1) | EP2170848B1 (enExample) |
| JP (2) | JP5140154B2 (enExample) |
| KR (1) | KR101541203B1 (enExample) |
| CN (1) | CN101842361B (enExample) |
| AR (1) | AR067444A1 (enExample) |
| AU (1) | AU2008269516B2 (enExample) |
| BR (1) | BRPI0813244B8 (enExample) |
| CA (1) | CA2691215C (enExample) |
| CL (1) | CL2008001898A1 (enExample) |
| CO (1) | CO6251251A2 (enExample) |
| CY (1) | CY1115836T1 (enExample) |
| DK (1) | DK2170848T3 (enExample) |
| EC (1) | ECSP109903A (enExample) |
| ES (1) | ES2525716T3 (enExample) |
| HR (1) | HRP20141174T1 (enExample) |
| IL (1) | IL202826A (enExample) |
| MY (1) | MY153258A (enExample) |
| NZ (1) | NZ581942A (enExample) |
| PE (1) | PE20090547A1 (enExample) |
| PL (1) | PL2170848T3 (enExample) |
| PT (1) | PT2170848E (enExample) |
| RS (1) | RS53682B1 (enExample) |
| RU (1) | RU2479580C2 (enExample) |
| SG (1) | SG182958A1 (enExample) |
| SI (1) | SI2170848T1 (enExample) |
| TW (1) | TWI448288B (enExample) |
| UA (1) | UA98961C2 (enExample) |
| UY (1) | UY31183A1 (enExample) |
| WO (1) | WO2009001132A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20141174T1 (hr) * | 2007-06-27 | 2015-02-13 | Astrazeneca Ab | Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8969350B2 (en) * | 2008-12-18 | 2015-03-03 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| US9138441B2 (en) | 2009-12-31 | 2015-09-22 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| LT2598482T (lt) | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| WO2012156531A2 (en) * | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| SI2776394T1 (sl) | 2011-10-20 | 2019-05-31 | Oryzon Genomics, S.A. | Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1 |
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| RU2014144951A (ru) | 2012-04-10 | 2016-06-10 | Сумитомо Дайниппон Фарма Ко., Лтд. | Новое 1-замещенное производное индазола |
| EP2875001B1 (en) | 2012-07-18 | 2019-01-09 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9444925B2 (en) * | 2013-04-05 | 2016-09-13 | Microsoft Technology Licensing, Llc | Smartphone proximity card emulation |
| WO2015021128A1 (en) | 2013-08-06 | 2015-02-12 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| ES2812626T3 (es) | 2014-06-27 | 2021-03-17 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| PL3256218T3 (pl) | 2015-02-12 | 2025-03-31 | Imago Biosciences Inc. | Inhibitor kdm1a i jego zastosowanie w terapii |
| WO2017162304A1 (en) | 2016-03-24 | 2017-09-28 | Astrazeneca Ab | Crystalline form |
| AU2017245641A1 (en) * | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| KR102341660B1 (ko) | 2016-09-19 | 2021-12-23 | 노파르티스 아게 | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 |
| EP3529242A1 (en) * | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CN106674029B (zh) * | 2016-12-23 | 2018-08-21 | 四川久凌制药科技有限公司 | 一种他喷他多中间体的制备方法 |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| JP7450559B2 (ja) * | 2018-05-11 | 2024-03-15 | イマーゴ バイオサイエンシーズ インコーポレイテッド | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
| CA3130871A1 (en) * | 2019-03-22 | 2020-10-01 | David Tristram BROWN | Novel potassium channel inhibitors |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| PT4122926T (pt) * | 2021-04-14 | 2025-07-29 | Shionogi & Co | Derivados de triazina com atividade inibitória da replicação de vírus e composição farmacêutica que compreende os mesmos |
| CN113999129B (zh) * | 2021-11-23 | 2023-09-01 | 长沙普济生物科技股份有限公司 | 一种含酚羟基氨基酸表面活性剂的合成方法 |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128514A (en) * | 1996-09-06 | 2003-07-06 | Nippon Kayaku Kk | Acetamide derivatives, pharmaceutical compositions comprising them and a process for producing such derivatives |
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| CA2478936A1 (en) | 2002-03-14 | 2003-09-18 | Bayer Healthcare Ag | Monocyclic aroylpyridinones as antiinflammatory agents |
| EP1534391B1 (en) | 2002-07-19 | 2007-02-14 | Biovitrum AB | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
| US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP3962425B2 (ja) * | 2003-10-14 | 2007-08-22 | ファルマシア・コーポレーション | 炎症治療用置換ピラジノン化合物 |
| US7737143B2 (en) * | 2003-12-03 | 2010-06-15 | Ym Biosciences Australia Pty Ltd | Substituted pyrazines as kinase inhibitors |
| GB0402812D0 (en) * | 2004-02-09 | 2004-03-10 | Tanabe Seiyaku Co | Novel compounds |
| WO2006003517A1 (en) | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
| JP4496092B2 (ja) | 2005-01-12 | 2010-07-07 | 信越化学工業株式会社 | 光ファイバ母材の製造方法及び装置 |
| ES2412007T3 (es) | 2005-12-21 | 2013-07-09 | Janssen Pharmaceutica, N.V. | Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1 |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| CA2650970C (en) | 2006-05-04 | 2014-09-16 | Chroma Therapeutics Ltd. | P38 map kinase inhibitors |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| MX2008014921A (es) * | 2006-05-22 | 2008-12-09 | Janssen Pharmaceutica Nv | Derivados de piracinona sustituidos para uso como un medicamento. |
| TW200924754A (en) * | 2006-06-21 | 2009-06-16 | Du Pont | Pyrazinones as cellular proliferation inhibitors |
| CA2652859A1 (en) * | 2006-06-21 | 2007-12-27 | E.I. Du Pont De Nemours And Company | Pyrazinones as cellular proliferation inhibitors |
| HRP20141174T1 (hr) | 2007-06-27 | 2015-02-13 | Astrazeneca Ab | Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a |
-
2008
- 2008-06-25 HR HRP20141174AT patent/HRP20141174T1/hr unknown
- 2008-06-25 ES ES08776162.3T patent/ES2525716T3/es active Active
- 2008-06-25 EP EP08776162.3A patent/EP2170848B1/en active Active
- 2008-06-25 RS RS20140664A patent/RS53682B1/sr unknown
- 2008-06-25 SI SI200831338T patent/SI2170848T1/sl unknown
- 2008-06-25 UA UAA200913136A patent/UA98961C2/uk unknown
- 2008-06-25 BR BRPI0813244A patent/BRPI0813244B8/pt not_active IP Right Cessation
- 2008-06-25 MY MYPI20095582A patent/MY153258A/en unknown
- 2008-06-25 PT PT87761623T patent/PT2170848E/pt unknown
- 2008-06-25 KR KR1020107001749A patent/KR101541203B1/ko not_active Expired - Fee Related
- 2008-06-25 JP JP2010514138A patent/JP5140154B2/ja not_active Expired - Fee Related
- 2008-06-25 DK DK08776162.3T patent/DK2170848T3/en active
- 2008-06-25 CN CN2008801051412A patent/CN101842361B/zh not_active Expired - Fee Related
- 2008-06-25 NZ NZ581942A patent/NZ581942A/en unknown
- 2008-06-25 AU AU2008269516A patent/AU2008269516B2/en not_active Ceased
- 2008-06-25 CA CA2691215A patent/CA2691215C/en active Active
- 2008-06-25 SG SG2012047502A patent/SG182958A1/en unknown
- 2008-06-25 WO PCT/GB2008/050491 patent/WO2009001132A1/en not_active Ceased
- 2008-06-25 PL PL08776162T patent/PL2170848T3/pl unknown
- 2008-06-25 RU RU2009148673/04A patent/RU2479580C2/ru active
- 2008-06-26 TW TW097123868A patent/TWI448288B/zh not_active IP Right Cessation
- 2008-06-26 UY UY31183A patent/UY31183A1/es not_active Application Discontinuation
- 2008-06-26 US US12/147,132 patent/US8163905B2/en not_active Expired - Fee Related
- 2008-06-26 CL CL2008001898A patent/CL2008001898A1/es unknown
- 2008-06-27 AR ARP080102812A patent/AR067444A1/es active IP Right Grant
- 2008-06-27 PE PE2008001103A patent/PE20090547A1/es active IP Right Grant
-
2009
- 2009-12-17 IL IL202826A patent/IL202826A/en active IP Right Grant
- 2009-12-18 CO CO09145294A patent/CO6251251A2/es active IP Right Grant
-
2010
- 2010-01-27 EC EC2010009903A patent/ECSP109903A/es unknown
-
2012
- 2012-03-06 US US13/412,907 patent/US8299246B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/616,179 patent/US8889692B2/en active Active
- 2012-09-25 JP JP2012211413A patent/JP5539473B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-17 US US14/543,194 patent/US20150073136A1/en not_active Abandoned
- 2014-12-17 CY CY20141101059T patent/CY1115836T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531345A5 (enExample) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| CA2904338C (en) | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer | |
| RU2454411C2 (ru) | Производные хинолина | |
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| RU2009133255A (ru) | Комбинации бензотиазолона, агонистического в отношении бета-2-адренорецепторов | |
| JP5634526B2 (ja) | 代謝性疾患を処置するためのｐｐａｒ温存チアゾリジンジオン塩 | |
| CA2522435A1 (en) | Inhibitors of akt activity | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2013100371A (ja) | 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体 | |
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2013514369A (ja) | 糖尿病および他の代謝性疾患を処置するための、ｐｐａｒ温存チアゾリジンジオンおよび組み合わせ物 | |
| JP2006522813A5 (enExample) | ||
| JP7546297B2 (ja) | 皮膚障害の処置のためのチエニル－アニリン化合物 | |
| JP2018048143A5 (enExample) | ||
| JP2021500332A5 (enExample) | ||
| JP2005526696A5 (enExample) | ||
| JP2010500334A5 (enExample) | ||
| RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
| JP2007500160A5 (enExample) | ||
| KR20020090153A (ko) | 알콜중독 또는 알콜 의존을 위한 배합 치료 | |
| JP2008503575A5 (enExample) | ||
| EP4279138A3 (en) | Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof |